Everence Capital Management Inc. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,521 shares of the biopharmaceutical company’s stock after purchasing an additional 849 shares during the quarter. Everence Capital Management Inc.’s holdings in Gilead Sciences were worth $2,187,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Welch Investments LLC bought a new position in Gilead Sciences during the third quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences during the third quarter valued at approximately $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences during the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences during the second quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management boosted its stake in Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares during the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.
In related news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the sale, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gayle E. Wilson sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $77.92, for a total value of $4,675,200.00. Following the sale, the director now directly owns 182,258 shares of the company’s stock, valued at $14,201,543.36. The disclosure for this sale can be found here. Insiders have sold a total of 430,268 shares of company stock valued at $34,074,395 over the last three months. 1.30% of the stock is owned by corporate insiders.
Shares of Gilead Sciences, Inc. (GILD) opened at $81.10 on Thursday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. The stock has a market capitalization of $107,050.59, a P/E ratio of 23.30, a P/E/G ratio of -1.88 and a beta of 1.24.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the company earned $2.70 EPS. Gilead Sciences’s quarterly revenue was down 18.7% compared to the same quarter last year. analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.81%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 59.77%.
GILD has been the subject of a number of research reports. Maxim Group set a $94.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Monday, December 11th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research note on Wednesday, January 17th. Jefferies Group raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $81.19 to $93.00 in a research note on Friday, January 26th. Finally, Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price target for the company from $88.80 to $76.00 in a research note on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $88.61.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://ledgergazette.com/2018/03/15/gilead-sciences-inc-gild-shares-bought-by-everence-capital-management-inc.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.